Streetbeat News

Analyst Ratings

GOSS

Over the past 3 months, 5 analysts have published their opinion on Gossamer Bio (NASDAQ:GOSS) stock. The average price target is $5.4, implying an upside from the current price of $1.18. This represents a 22.86% decrease from the previous average price target of $7.00.

Portfolio Pulse from Benzinga Insights

August 11, 2023 | 6:00 pm

IDYA

IDEAYA Biosciences (NASDAQ:IDYA) has received positive analyst ratings in the last quarter, with 1 bullish and 4 somewhat bullish ratings. The average 12-month price target for the company has increased by 8.62% to $34.4, with a high of $40.00 and a low of $32.00.

Portfolio Pulse from Benzinga Insights

August 11, 2023 | 6:00 pm

LUNA

Northland Capital Markets analyst Tim Savageaux maintains a Market Perform rating on Luna Innovations and raises the price target from $7 to $8.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 5:59 pm

JYNT

Roth MKM analyst George Kelly maintains a 'Buy' rating on Joint (NASDAQ:JYNT) but has lowered the price target from $21 to $16.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 5:57 pm

GTBIF

HITI

INLB

At the recent Benzinga Cannabis Capital Conference, industry leaders emphasized the importance of data in understanding consumers and driving business growth in the cannabis sector. Sarah Kabakoff, VP of business development at Dutchie, and Mike Weinberger, CEO of Item 9 Labs Corp. (OTCPK: INLB), highlighted the need for businesses to utilize their data efficiently. The panel also included Wendy Berger, board member of Green Thumb Industries Inc (OTCQX:GTBIF), and Raj Grover, founder, president & CEO of High Tide Inc (NASDAQ:HITI).

Portfolio Pulse from Joana Scopel

August 11, 2023 | 5:57 pm

AVTA

Cantor Fitzgerald analyst Josh Siegler has maintained an Overweight rating on Avantax (NASDAQ:AVTA) but lowered the price target from $29 to $27.

Portfolio Pulse from richadhand@benzinga.com

August 11, 2023 | 5:56 pm

YETI

Piper Sandler analyst Peter Keith maintains an Overweight rating on YETI Holdings and raises the price target from $55 to $57.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 5:56 pm

CPRX

Cantor Fitzgerald analyst Charles Duncan maintains an Overweight rating on Catalyst Pharmaceuticals (NASDAQ:CPRX) and raises the price target from $25 to $27.

Portfolio Pulse from richadhand@benzinga.com

August 11, 2023 | 5:54 pm

ALXO

Cantor Fitzgerald analyst Alethia Young has maintained an Overweight rating on ALX Oncology Holdings (NASDAQ:ALXO) but lowered the price target from $22 to $18.

Portfolio Pulse from richadhand@benzinga.com

August 11, 2023 | 5:54 pm

BABA

Truist Securities analyst Youssef Squali has maintained a 'Buy' rating on Alibaba Group Holding (NYSE:BABA) and raised the price target from $130 to $135.

Portfolio Pulse from Benzinga Newsdesk

August 11, 2023 | 5:54 pm